Indication:Melanoma – advanced (unresectable or metastatic) melanoma in adults expressing a BRAF V600 gene mutation
Non-small cell lung cancer (NSCLC) in combination with trametinib with a BRAF V600 mutation
Stage III Melanoma with a BRAF V600 mutation, following complete resection.
NICE guidelines [NG14]
Melanoma: assessment and management – full guidance at: http://www.nice.org.uk/guidance/ng14/resources/melanoma-assessment-and-management-1837271430853
Dabrafenib is recommended, withinn its marketing authorisation, as an option for treating unresectable or metastatic BRAF V600 mutation-positive melanoma only if the company provides dabrafenib with the discount agreed in the patient access scheme.